Peer-review started: June 7, 2015
First decision: September 28, 2015
Revised: November 17, 2015
Accepted: December 17, 2015
Article in press: December 18, 2015
Published online: March 26, 2016
Processing time: 285 Days and 5.5 Hours
Iron is essential for all organisms including microbial, cancer and human cells. More than a quarter of the human population is affected by abnormalities of iron metabolism, mainly from iron deficiency and iron overload. Iron also plays an important role in free radical pathology and oxidative damage which is observed in almost all major diseases, cancer and ageing. New developments include the complete treatment of iron overload and reduction of morbidity and mortality in thalassaemia using deferiprone and selected deferiprone/deferoxamine combinations and also the use of the maltol iron complex in the treatment of iron deficiency anaemia. There is also a prospect of using deferiprone as a universal antioxidant in non iron overloaded diseases such as neurodegenerative, cardiovascular, renal, infectious diseases and cancer. New regulatory molecules of iron metabolism such as endogenous and dietary chelating molecules, hepcidin, mitochondrial ferritin and their role in health and disease is under evaluation. Similarly, new mechanisms of iron deposition, removal, distribution and toxicity have been identified using new techniques such as magnetic resonance imaging increasing our understanding of iron metabolic processes and the targeted treatment of related diseases. The uniform distribution of iron in iron overload between organs and within each organ is no longer valid. Several other controversies such as the toxicity impact of non transferrin bound iron vs injected iron, the excess levels of iron in tissues causing toxicity and the role of chelation on iron absorption need further investigation. Commercial interests of pharmaceutical companies and connections to leading journals are playing a crucial role in shaping worldwide medical opinion on drug sales and use but also patients’ therapeutic outcome and safety. Major controversies include the selection criteria and risk/benefit assessment in the use of deferasirox in thalassaemia and more so in idiopathic haemochromatosis, thalassaemia intermedia and ex-thalassaemia transplanted patients who are safely treated with venesection. Iron chelating drugs can override normal regulatory pathways, correct iron imbalance and minimise iron toxicity. The use of iron chelating drugs as main, alternative or adjuvant therapy is in progress in many conditions, especially those with non established or effective therapies.
Core tip: Abnormalities of iron metabolism including iron deficiency and overload affect more than a quarter of the world’s population. Iron also plays a major role in free radical pathology and associated tissue damage. Iron chelating drugs can override normal regulatory pathways, correct iron imbalance and minimise iron toxicity. Deferiprone and especially its combination with deferoxamine can completely treat iron overload in thalassaemia. Deferiprone can minimise the toxic effects of pathological iron in neurodegenerative, renal and other diseases. Controversies in the risk/benefit assessment for the use of deferasirox in many conditions appear to involve commercial influence on academic journals and physicians.